92% Early Parkinson's Classification Accuracy in the WATCH-PD Study
Learn more about how our sensors, wearables, and machine-learning technology was deployed in the research.
The Clinical ink team collaborated with partners in academia and the pharmaceutical industry in WATCH-PD, a research study to validate remote, mobile assessments for use in capturing digital biomarkers or digital endpoints in Parkinson’s Disease (PD).
Using the rich mobile and sensor data collected by Clinical ink technology, our machine learning-enabled analysis model distinguished healthy volunteers from patients with early-stage PD, but whose early signs of Parkinson’s may not have otherwise been obvious. This provides preliminary support for the use of Clinical ink technology in generating digital biomarkers associated with PD status and improving Parkinson’s Disease classification.
Ultimately, such evidence should lead to regulatory acceptance and widespread adoption of the assessments in Parkinson’s clinical trials and clinical development.
